Prescribing of GLP-1 receptor agonists for U.S. children aged eight to 11 with obesity has increased dramatically despite the medicines not being FDA approved for chronic weight management below age 12, according to a new study published in Pediatrics. NYU Langone researchers analyzed repeated annual cohorts covering more than 3.52 million children with obesity but without diabetes between January 2019 and June 17, 2026. Across the overall study period, 20,282 children in this age group received prescriptions for Saxenda, Wegovy or Zepbound, while the authors calculated that prevalent prescribing increased approximately 310-fold from 2019 to 2026.
The findings need careful interpretation because they document prescribing behavior rather than proving that GLP-1 therapy is safe or effective for children below age 12. Across the full seven-and-a-half-year cohort, only about 0.6% of eligible children received one of the medicines, and researchers found that prescribing was heavily concentrated among children with severe obesity or obesity-related medical complications. The study therefore shows that off-label use is moving into younger ages, but it does not provide weight-loss outcomes, adverse-event rates or long-term developmental evidence for these patients.
How did GLP-1 prescribing change from 2019 through 2026?
The Pediatrics research brief used Epic Cosmos electronic health-record data and examined children aged eight through 11 who had obesity but not diabetes. The authors reported prevalent GLP-1 prescribing increasing from 0.03% in 2019 to 9.3% in the 2026 annual cohort, which they described as a 310-fold increase. Across the entire 3,520,531-child population spanning all study years, 0.6% received a GLP-1 prescription.
Those percentages describe different denominators and time frames, which is why the 9.3% 2026 figure should not be confused with the 0.6% cumulative proportion across the full multi-year dataset. The study’s core conclusion is nevertheless clear: use remains uncommon overall but has accelerated rapidly.
NYU Langone said 20,282 children aged eight to 11 received a GLP-1 prescription during the study period. Most were not children with relatively mild excess weight. About 93.7% of those prescribed the drugs had severe obesity, while 65.2% had at least one obesity-related illness such as hypertension, elevated cholesterol or sleep apnea.
Are Wegovy, Saxenda and Zepbound FDA approved for children under 12?
No. The drugs examined in this weight-management analysis are not FDA approved for chronic obesity treatment in children younger than 12. Wegovy and Saxenda have established adolescent obesity indications beginning at age 12 under specified criteria, while Zepbound’s pediatric obesity development program has been proceeding separately.
That means prescriptions in eight- to 11-year-olds are off-label. Off-label prescribing is not inherently improper or illegal. Physicians frequently use approved medicines outside the exact age, disease or dose described in their labels when they conclude that available evidence and the individual patient’s condition justify doing so.
The threshold for doing this in children can be particularly demanding because growth, puberty, nutrition and long-term developmental consequences must be considered. A medication intended to alter appetite and body weight over years raises questions that are different from prescribing the same therapy to a middle-aged adult.
Why are physicians considering weight-loss medicines in children this young?
Severe pediatric obesity is not simply a cosmetic issue. Children can develop hypertension, abnormal lipids, sleep apnea, fatty liver disease, orthopedic problems and early metabolic dysfunction, while severe obesity during childhood frequently persists into adolescence and adulthood.
The American Academy of Pediatrics has moved away from recommending prolonged watchful waiting when obesity is severe. Its clinical practice guidance allows clinicians to consider pharmacotherapy in selected children aged eight to 11 as an adjunct to intensive health-behavior and lifestyle treatment, taking into account medication indications, benefits and risks.
The new prescribing study suggests that clinicians are generally using GLP-1 medicines selectively rather than broadly across every child with obesity. Children with obesity-related comorbidities had prescription rates of 188.9 per 10,000, substantially above the overall group, while the overwhelming majority of treated children had severe obesity.
That pattern is consistent with physicians reserving off-label treatment for children whose medical risk may justify greater uncertainty.
Why were 11-year-olds prescribed GLP-1 drugs more often than eight-year-olds?
Age showed a strong gradient. Eleven-year-olds had a prescription prevalence of 79.5 per 10,000 compared with 41.5 per 10,000 among eight-year-olds. Girls were also more likely to receive prescriptions than boys, with rates of 75.9 versus 42.8 per 10,000.
Several factors could contribute. Physicians may feel more comfortable treating an 11-year-old who is approaching the age covered by adolescent drug labels than an eight-year-old with many more years of growth remaining. Pubertal status, disease severity and patient ability to manage injections may also influence decisions.
The observational dataset cannot determine exactly why individual physicians prescribed the drugs. It identifies associations rather than proving that age or sex itself caused a prescribing decision.
That limitation should prevent overinterpretation of apparent sex differences. Girls may have presented with different severity, comorbidities, healthcare utilization or treatment preferences than boys in ways not completely captured by the summary statistics.
What does the study show about inequality in access to GLP-1 treatment?
Children living in areas with lower social vulnerability were more likely to receive GLP-1 prescriptions. The rate was 76.1 per 10,000 among children in low-vulnerability settings compared with 49.2 per 10,000 among those in high-vulnerability settings.
That difference matters because obesity and its medical complications frequently disproportionately affect socioeconomically disadvantaged families. If the children at highest long-term health risk have more difficulty accessing specialists or expensive medicines, pharmacological advances could widen existing health disparities rather than close them.
Insurance coverage is a likely contributor. Another Pediatrics study published earlier in 2026 found that treatment interruptions among adolescents prescribed GLP-1 therapy were common, with cost and insurance coverage among the most frequent reasons.
The younger-child study was not designed to quantify payer denials or out-of-pocket spending, but its socioeconomic pattern adds another reason to examine whether access follows clinical need or financial resources.
Does this study show that GLP-1 medicines work for children aged eight to 11?
No. There are no weight-loss efficacy results in this analysis. Researchers examined whether prescriptions appeared in electronic health records, not how much weight patients lost, whether comorbidities improved or how many children discontinued treatment.
This distinction is particularly important given public interest in GLP-1 medicines. A 310-fold increase in prescribing can easily be misread as evidence of successful treatment when it actually describes physician behavior.
The study also does not establish long-term safety. Researchers did not track gastrointestinal side effects, gallbladder events, pancreatitis, nutritional deficiencies, changes in growth or other treatment outcomes.
Separate controlled pediatric trials are required to answer those questions. Zepbound’s FDA postmarketing pediatric program, for example, includes planned study work in children aged six through 11 rather than assuming adult efficacy and safety apply automatically to younger patients.
Why is long-term safety particularly important before routine use below age 12?
An adult who begins obesity treatment at age 45 may require therapy for decades. A child beginning at eight could theoretically face a much longer period of exposure if obesity pharmacotherapy functions like treatment for other chronic diseases.
Children are also actively growing. Appetite suppression, caloric intake and body composition have to be considered in relation to bone development, puberty and nutritional requirements rather than weight alone.
The available evidence from adolescent GLP-1 studies is encouraging in terms of weight reduction, but safety cannot simply be extrapolated downward by four years. The FDA’s decision to require dedicated younger-pediatric studies reflects this uncertainty.
Another unanswered question is what happens after discontinuation. Adults commonly regain weight after stopping incretin-based obesity therapy. If the same pattern occurs in young children, families and physicians need to understand whether starting treatment implies potentially prolonged therapy rather than a temporary intervention.
Does the AAP recommendation conflict with FDA labeling?
Not necessarily. FDA labeling establishes the uses for which a manufacturer has demonstrated sufficient evidence to obtain marketing authorization. Clinical-practice guidelines can address medical decision-making more broadly, including circumstances in which clinicians may consider an approved drug outside its labeled indication.
The AAP guideline does not mean every eight-year-old with obesity should receive GLP-1 therapy. It supports consideration of pharmacotherapy within comprehensive obesity treatment when the child’s severity, risks and available evidence justify it.
The new data suggest that physicians are using this discretion increasingly often. Whether that trend is running ahead of the evidence is the important clinical-policy question.
Because 93.7% of treated children had severe obesity and nearly two-thirds had at least one related illness, the prescribing pattern appears concentrated in higher-risk patients rather than casual cosmetic weight reduction.
What should families take away from the 310-fold increase?
The number should not be interpreted as a recommendation to seek GLP-1 treatment for every younger child with obesity. It demonstrates that specialist practice is already changing before formal FDA weight-management indications extend below age 12.
For families considering treatment, the relevant questions are individual: severity of obesity, existing complications, previous intensive lifestyle treatment, psychological context, potential adverse effects, access to nutritional support and whether long-term follow-up is available.
The broader healthcare system now needs evidence to catch up with practice. Researchers need prospective trials establishing dosing, efficacy, safety, growth outcomes and what happens when treatment stops.
More than 20,000 prescriptions in eight- to 11-year-olds mean off-label pediatric GLP-1 treatment is no longer a theoretical discussion. It is already occurring in U.S. clinical practice. The Pediatrics study does not tell physicians whether that practice is right or wrong. It tells researchers and regulators that the question has become urgent enough that waiting for anecdotal experience is no longer sufficient.
